John A Josey

This inventor holds 25 USPTO granted patents and 3 published patent applications, plus 2 CIPO patents and 5 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Peloton Therapeutics, Inc., Amgen Inc., Array Biopharma Inc.. Active years: 2000-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John A Josey. Retrieved from https://idiyas.com/inventor/john-a-josey

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 25 (Patent Applications = 3)

% Patents Active = 72.0

CIPO Patents = 2

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 3.9

ph-index = 8

Forward Citations = 257(Granted Patents)

Location History:

Boulder, CO (US) (2005)
Longmont, CO (US) (2000 - 2014)
Dallas, TX (US) (2014 - 2024)

Company Filing History:

13 out of 18

Peloton Therapeutics, Inc.

where one patent can have more than one assignee

Years Active: 2000-2024

Loading Chart...

Areas of Expertise:

Aryl Ethers

HIF-2-alpha Inhibitors

Glioblastoma Treatment

Pulmonary Arterial Hypertension

Benzimidazole Derivatives

Cyclic Sulfone

mTOR Inhibitors

Carboxylic Acid Derivatives

Substituted Pyridine Compounds

Immunotherapeutic Agents

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. RE49948 - Aryl ethers and uses thereof (2024-04-30),

2. 10807948 - Aromatic compounds and uses thereof (2020-10-20),

3. 10786480 - Combination therapy of a HIF-2-α inhibitor and an immunotherapeutic agent and uses thereof (2020-09-29),

4. 10597366 - Aryl ethers and uses thereof (2020-03-24),

5. 10512626 - Compositions for use in treating glioblastoma (2019-12-24),

6. 10335388 - Combination therapy of a HIF-2-alpha inhibitor and an immunotherapeutic agent and uses thereof (2019-07-02),

7. 10278942 - Compositions for use in treating pulmonary arterial hypertension (2019-05-07),

8. 10144711 - Aryl ethers and uses thereof (2018-12-04),

9. 10040767 - Benzimidazole derivatives and uses thereof (2018-08-07),

10. 9969689 - Aryl ethers and uses thereof (2018-05-15),

11. 9908845 - Aryl ethers and uses thereof (2018-03-06),

12. 9896418 - Aryl ethers and uses thereof (2018-02-20),

13. 9884843 - Cyclic sulfone and sulfoximine analogs and uses thereof (2018-02-06),

14. 8865726 - Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors (2014-10-21),

15. 8680114 - AKT protein kinase inhibitors (2014-03-25),

Title: Innovator Spotlight: John A. Josey

Introduction

John A. Josey, located in Dallas, TX, is a renowned inventor with a remarkable portfolio of 25 patents. His contributions to the field of pharmaceuticals and biomedical innovations make him a significant figure in the industry.

Latest Patents

Among his latest patents, John has developed innovative pharmaceutical compounds aimed at targeting HIF-2α, which plays a critical role in tumor development and progression. One notable patent, titled "Aryl ethers and uses thereof," discloses HIF-2α inhibitors and methods for treating cancer. The compounds showed potency in various assays and demonstrated tumor size reduction in xenograft models. Another groundbreaking patent, "Aromatic compounds and uses thereof," features substituted indane derivatives that serve as HIF-2α inhibitors, with applications for treating renal cell carcinoma and von Hippel-Lindau disease.

Career Highlights

Throughout his career, John A. Josey has worked with prominent companies, including Peloton Therapeutics, Inc. and Amgen Inc. His expertise has contributed significantly to advancements in therapeutic techniques and drug development.

Collaborations

John has collaborated with talented individuals such as Stephen T. Schlachter and Eli M. Wallace. Their cooperation on various projects has enriched the scope of research and innovation within the pharmaceutical field.

Conclusion

John A. Josey’s inventive spirit and contributions to medical technology exemplify the impact of innovation in improving health outcomes. His ongoing work continues to inspire the next generation of inventors and researchers in the quest to tackle complex health challenges.

Profile summary based on public USPTO records.